1. Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy
- Author
-
Eiji Oguma, Ryoji Hanada, Takahisa Tainaka, Hiroshi Kawashima, Hiroshi Kishimoto, Makiko Mori, Yujiro Tanaka, Hiroo Uchida, Yuki Arakawa, Hizuru Amano, and Katsuyoshi Koh
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Neoplasm, Residual ,medicine.medical_treatment ,Tumor resection ,Disease-Free Survival ,Resection ,Neuroblastoma ,Vanilmandelic Acid ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,030212 general & internal medicine ,Neoplasm Staging ,Retrospective Studies ,Chemotherapy ,Tumor size ,business.industry ,Infant, Newborn ,Infant ,Homovanillic Acid ,General Medicine ,Prognosis ,medicine.disease ,Tumor Pathology ,Combined Modality Therapy ,Tumor Burden ,Treatment Outcome ,Child, Preschool ,030220 oncology & carcinogenesis ,Pediatrics, Perinatology and Child Health ,Female ,Surgery ,Radiology ,Intermediate risk ,business - Abstract
Background/purpose The prognosis of patients with intermediate-risk neuroblastoma is favorable; therefore, a reduction therapy is desired. However, the long-term prognosis of those with residual tumor is unclear. The aim of this study was to clarify the necessity of residual tumor resection. Methods We retrospectively reviewed the records of patients diagnosed with intermediate-risk neuroblastoma who either were treated by chemotherapy only (nonresection group; n=16), or received postchemotherapy tumor resection (resection group; n=9). Results In the nonresection group, tumor size decreased in 14 patients; 5 had no detectable local tumor at the end of the follow-up period. Tumor size increased in 2 patients 1.5–2.5years postchemotherapy. Both patients received additional treatment and survived. All patients survived during the median follow-up time of 127months. In the resection group, 5 patients received complete resections and 4 patients received nearly complete resections. All patients survived during the median follow-up time of 84months. In 8 out of 9 resected tumors, regression or maturation was pathologically induced by chemotherapy-only treatment. Conclusion Patients with intermediate-risk neuroblastoma with or without postchemotherapy residual tumor resection had an excellent long-term outcome. The tumor pathology with intermediate-risk neuroblastoma might be susceptible to change to regression or maturation by chemotherapy. Level of evidence IV
- Published
- 2018